Orforglipron (Foundayo) FDA approval, launch, Novo cross-trial rivalry and China/Asia/US manufacturing readiness
Key Questions
When was Foundayo approved by the FDA?
The FDA approved Foundayo (orforglipron), Eli Lilly's GLP-1 pill for weight loss, on April 1, 2026, in a record 50-day review. This approval targets adults with obesity or overweight with weight-related conditions.
What is the pricing and availability of Foundayo?
Foundayo launched via LillyDirect at $149 per month, $25 for insured patients, and $50 for Medicare patients. Shipments have already started.
What did Eli Lilly's CEO say about production scaling?
CEO Dave Ricks stated that Eli Lilly is ready to scale production of the newly approved weight-loss pill Foundayo. The company anticipates over 40 global approvals in 2026.
Where will Foundayo be manufactured?
Eli Lilly's Houston facility, a $6.5 billion API plant, began shipping ingredients on April 6 and will operate until around 2030. A $3.5 billion plant in Lehigh, Pennsylvania, also supports production.
How has Eli Lilly's stock performed recently after the approval?
Eli Lilly's stock traded between $907 and $963, closing at $932, with gains of 4-6.5% following the news but down 13% year-to-date. Investors have heavily searched the stock per Zacks data.
What are key analyst price targets for Eli Lilly post-approval?
Leerink issued an Outperform rating with a $1104 target, citing Medicare obesity expansion for 40 million patients. Bank of America set a $1294 target.
What is the competitive dynamic with Novo Nordisk?
Novo Nordisk highlighted its Wegovy tablet's superiority in the ORION trial, positioning it against Foundayo in the oral GLP-1 space.
Why is Foundayo significant for weight loss treatment?
Foundayo offers a convenient pill alternative to injections like Wegovy, appealing to patients for cost and ease. Adults taking it lost significant weight on average in trials.
FDA approved Apr 1, 2026 (record 50-day); launch live LillyDirect $149/mo/$25 insured/$50 Medicare; shipments started; CEO Ricks scaling readiness/40+ global approvals 2026; Houston $6.5B API shipping Apr6/~2030; PA Lehigh $3.5B; Novo ORION touts Wegovy tablet superiority; Leerink Outperform/$1104 on Medicare obesity expansion/40M pts; BofA $1294; stock $907-963/$932 +4-6.5%/-13% YTD; Zacks heavy searches.